<SEC-DOCUMENT>0001193125-11-151080.txt : 20110526
<SEC-HEADER>0001193125-11-151080.hdr.sgml : 20110526
<ACCEPTANCE-DATETIME>20110526090052
ACCESSION NUMBER:		0001193125-11-151080
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110526
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110526
DATE AS OF CHANGE:		20110526

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		11872682

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): May&nbsp;26, 2011 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200,
Broomfield, CO 80021 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not
Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01 Other Events </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;26, 2011, ARCA biopharma, Inc., issued a press release announcing that it plans to expand the development of Gencaro, its lead cardiovascular drug candidate, to atrial fibrillation and to
conduct a Phase III clinical trial to evaluate Gencaro in patients who have atrial fibrillation and heart failure with reduced left ventricular ejection fraction. The press release is attached as Exhibit&nbsp;99.1 hereto, the contents of which are
incorporated herein by reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01 Financial Statements and Exhibits </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma announces planned expansion of Gencaro development to atrial fibrillation&#148;, dated May&nbsp;26, 2011.</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: May&nbsp;26, 2011 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Patrick M. Wheeler</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick M. Wheeler</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR></TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma announces planned expansion of Gencaro development to atrial fibrillation&#148;, dated May&nbsp;26, 2011.</FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g194240g45q08.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor
Relations&nbsp;&amp; Corporate Communications </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com</U> </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA BIOPHARMA ANNOUNCES PLANNED EXPANSION
OF GENCARO </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DEVELOPMENT TO ATRIAL FIBRILLATION </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Phase 3 Trial of Gencaro in Heart Failure Patients with Atrial Fibrillation Planned To Begin </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Enrollment in 1H 2012 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gencaro Potentially First
Genetically-Targeted Treatment for Prevention of Atrial </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fibrillation </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, May&nbsp;26, 2011</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted
therapies for cardiovascular diseases, today announced that it is planning to expand the development of Gencaro, its lead cardiovascular drug candidate, to atrial fibrillation, a disease that affects more than 2.4&nbsp;million patients in the United
States. Subject to obtaining additional funding, the Company anticipates initiating patient enrollment of a Phase 3 clinical trial in the first half of 2012 to evaluate Gencaro in patients who have symptomatic atrial fibrillation and heart failure
with reduced left ventricular ejection fraction (HFREF). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;At ARCA, we believe a personalized medicine approach to drug development,
tailoring medical treatment to the individual genetic characteristics of each patient, can enable more effective therapies, improve patient outcomes and reduce healthcare costs,&#148; said Dr.&nbsp;Michael&nbsp;R. Bristow, President and Chief
Executive Officer of ARCA. &#147;If our development program for Gencaro in atrial fibrillation successfully confirms atrial fibrillation data from the prior BEST study, Gencaro has the potential to be the first genetically targeted treatment for the
prevention of this important cardiovascular disorder.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Atrial Fibrillation </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Atrial fibrillation is a disorder in which the normally regular and coordinated contraction pattern of the heart&#146;s two small upper chambers (the
atria) becomes irregular and uncoordinated. The irregular contraction pattern associated with atrial fibrillation causes blood to pool in the atria, predisposing the formation of clots. These clots may travel from the heart and become lodged in the
arteries leading to the brain and other organs, thereby blocking necessary blood flow and potentially resulting in stroke. In addition, in patients with HFREF, new onset atrial fibrillation may also contribute to worsening heart failure and
increased risk of death. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Studies estimate atrial fibrillation affected between 2.4 and 3&nbsp;million Americans in 2005. Those
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
same studies estimate the prevalence of atrial fibrillation will likely increase to between 3.8&nbsp;million and 4.8&nbsp;million by 2025. Industry estimates expect the atrial fibrillation drug
market in developed countries to increase more than eight-fold, from $843 million in 2009 to $6.8 billion in 2019. The Company believes there is an unmet medical need for new atrial fibrillation treatments that have fewer side effects than currently
available therapies and are more effective, particularly in patients with HFREF, where most of the approved atrial fibrillation drugs are contra-indicated or have warnings in their prescribing information. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Gencaro Data in Atrial Fibrillation </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-right:8%;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Clinical data from BEST, a Phase 3 trial in 2,708 patients with advanced heart failure, indicate that Gencaro may have a potentially enhanced and pharmacogenetically-influenced effect in reducing and
preventing atrial fibrillation. In that trial, patients in the Gencaro arm demonstrated a reduction in the risk of new onset atrial fibrillation time to event compared to patients in the placebo arm of 41% (atrial fibrillation measured as an adverse
event/serious adverse event or as detected on surveillance ECGs, time to event analysis, p = 0.0004). In a 1,040 patient DNA substudy of BEST, Gencaro exhibited pharmacogenetic enhancement and differentiation for atrial fibrillation prevention in
patients with a specific genotype (beta</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">1</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">389 arginine
homozygous (Arg/Arg) adrenergic receptor (AR); approximately 47% of the patients). These patients experienced a 74% (p = 0.0003) reduction in risk of atrial fibrillation versus no detectable reduction in patients who had alternative genotypes
(beta</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">1</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">389 Gly carriers; 53% of the patients). The Company
believes this data supports the potential ability of Gencaro to prevent atrial fibrillation in patients who have the genotype the Company believes responds most favorably to Gencaro. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In prior placebo controlled trials in chronic HFREF, most studies comparing beta-blockers to placebo have detected a positive signal for prevention of atrial fibrillation, with an event rate reduction
averaging approximately 27%, even though atrial fibrillation had not been a pre-specified primary or secondary endpoint in these studies. Currently, no beta-blocker has been approved by the U.S. Food and Drug Administration for the prevention of
atrial fibrillation in heart failure patients. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Gencaro Phase 3 Atrial Fibrillation Clinical Trial </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company plans to conduct a Phase 3, multi-center, randomized, double-blind clinical trial of Gencaro in approximately 300-400 new onset atrial
fibrillation patients with HFREF. The Company believes the planned study will provide important clinical data on the safety and efficacy of Gencaro in this patient population and additional information on the pharmacogenetic selectivity of Gencaro.
The primary endpoint of the trial will be time to recurrent symptomatic atrial fibrillation after electrical cardioversion. The atrial fibrillation development program was recently presented by Dr.&nbsp;Bristow at the Heart Failure Congress 2011,
organized by the Heart Failure Association of the European Society of Cardiology. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is planning for the atrial
fibrillation trial to compare Gencaro to the beta-blocker metoprolol CR/XL in patients with the genotype (homozygous arginine position of the beta</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUB
STYLE="vertical-align:baseline; position:relative; top:.4ex">1</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">389 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
adrenergic receptor) in which Gencaro appears to demonstrate therapeutic enhancement. Metroprolol CR/XL does not appear to have enhancement of efficacy in patients with this genotype. The Company
believes the planned trial would take approximately two years from enrollment of the first patient to completion. Subject to obtaining additional financing, the Company anticipates initiating patient enrollment in the trial in the first half of
2012. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an investigational, pharmacologically
unique beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure and the prevention of atrial fibrillation in patients with heart failure. ARCA has identified common genetic variations in the cardiovascular system
that it believes interact with Gencaro&#146;s pharmacology and may predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted heart failure and/or atrial fibrillation prevention treatment. ARCA is
collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. For more information please visit <U>www.arcabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148;
for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the ability of genetic variations to predict individual patient response to
Gencaro; the potential for Gencaro to be the first genetically-targeted heart failure and/or atrial fibrillation prevention treatment; the projected increase in prevalence of atrial fibrillation; the projected increase in the size of the atrial
fibrillation drug market in developed countries; and, the potential for the planned atrial fibrillation clinical trial provide important data on the safety and efficacy of Gencaro in the trial population. Such statements are based on
management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the
risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; the protection and market exclusivity provided by the
Company&#146;s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in
ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2010 and subsequent filings. The Company disclaims any intent or obligation to update these
forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g194240g45q08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g194240g45q08.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`40#A`P$1``(1`0,1`?_$`,0```$$`P$!`0``````
M```````'"`D*`00&!0,"`0$!``("`P$!`````````````0(#!P@%!@D$"A``
M``8!`P($`@4)`PH'`````0(#!`4&!P`1"!(3(3$4"4%189$B4A5QH;'1,B,6
M%PJ!0K+!,T,DU)56)W<8\.%R-+0E.1$``0,"!0(!!P4-!@<``````0`"`Q$$
M(3$2!09!!U%A<2(R$Q0(@9%28A6AL=%"DM(C,U-C)!8)\()#5)15P;(T1&1T
M%__:``P#`0`"$0,1`#\`O-YBS+4\*5A2RVI954RZHLX2$9=L\K.R/:[@-6::
MAR$312+]I=<X@F@0=QW$2E-Q#WI[U<,[&<1/*N7/>YTCS':VT6DSW4U*B.)K
MB`&M'I2RN(9$S%Q)+6N]@XWQK<N4;A[AMP`H*O>[U(V^+CXG)K1BXY=2(SI[
MW`,Q2K]0U8K]-KT>"A^PU<LI">>"D(CVP=O5'[!`ZH%\Q303+O\`#7ROY/\`
MU&.\FXWSI.,;?LFV;8''0R2.:[E+>FN0RPL+O'1$P+G2S[/<<MX@+^:YFFIB
M0YL;:^1NEQIYW%80YF<D%@2/O2NE9,%4Q+5G`@8HF,0=A&8\RG()1^0AKQS/
MCL^)R8,,+=C+)&!S3[@^A!)'^9S!!!'0@K)_;+A#*C^*J#0_I1^8O3<\O>2#
M=%JJ)J8(.6XKEWJJ^VP.5VX[;3(^&Z`_VZ\C=_&Q\4EI!!.]FQZ9HB\?P#^D
MCV8?Q/BSKU7YV=N>#O>YH]ZJTT_6CP!^AY5S[SFUR,8E3.L-)V5`QR!_"SD#
M"0IQ3ZA#\9_9$Y1`/GL.O"7/Q\_$C9ACKK["9[0$BM@_($MK_P!3D2"!XT*_
M;%VLX7,2&>]5'[T?F)7L4^X&L[E&D-EZ`C8QDZ43;_Q;6R.R-X\YQZ07F(5V
MN\5]&!A#N*MU1%(NX]LP;[<\=H/ZBS[[=H=E[R[=:VMA,YK/M"R]H(X2<-=S
M;2.D=[.M-4D4A+&U/LG"I'K/(>SWLH'7/&YGR2M!/L9:5=3HQX#1J\`X8G\8
M*2Y!ZFZ00=-5T7+9RBDX;.4#D50<-UR%51715((D4253,!BF`1`0$!#7U+MK
MBWO+>.[M'LEM96->Q["'->QP#FN:X5#FN!!!!((-0N#'L?&\QR`MD:2"#@01
M@01T(.:^O>/]'U:W+%'>/]'U:(OPHZ!%-1991)%%%,ZJJJIB)I)))E$ZBJJA
MQ*1--,A1$QA$```W'1$EV&,Z8LY#4)CD_"UVB<@4.2DIR'9V.'([3:JR5;E7
M4+,M!1?MF;Q)1I(,SE`3IE*JF)5$Q,F<AC%2",TJG>/]'U:*+(*J".P;"(_1
MHB:BRYY\+)!^]BVO+3CL>1CG;AB^9J9<I#9PU>-%U&SIJLFYF41(NW<)&(<H
M^)3%$!T5TN\%ZDIS:X?0B)G$KRKXZ,T2D`XG4S'C\WV!\0$`2GCF'</D&^B4
M*\FN\]>%=MD21%<Y:<=I:35.5-%DWRW22KK*&'8B2)5IA(%5#B.P%*(B(^&B
M4*=,RDVTDT;2$<\:2#!XD1PS?,5T7;-V@H`&(LV=-SJ(+I'`=P,0P@/ST46S
MWC_1]6B([Q_H^K1$D.7.0V$<!Q19K->7<=8LCE4Q4;JWFUPU>6>D`PE$8]D_
M=I/I`0,40V024'P'16A*9>O[Q7MS(BJ9'DE'2C-`3%6EX+'F5YR!2$G[0FG(
MNC.HH2%^\"HE^G170Y=K5/=1]O*Z`F,%R^PL`JFZ2$G;$>J*]7W3(VEI#*$,
M'QW#ST32[P3W*Q;J[=J]#VVFV"%M=5L+!"4@;)7I%I,0<U&N2]3=_%RC!5=F
M^9KE\2*)G,0WP'18KW>\?Z/JT1'>/]'U:(DHA\\XHL&8KEQ_AKS#R&8\>U6O
MW>Y4-`KO\6@:O:%CH0DHZ5.V*P4*Z.!!.DDL=9`BZ)E2$*LD)BM#2O1*OWC_
M`$?5HHL@L?</+S#X:(MK1%"CSIGY.=SVXKZZQS,*I78)E&-MQ[21I=H29D'(
M$WV[SE1TF0QO,2HD#R`-?"[^H%RG<]X[_2[!<O<=MV?;+6*!GXH=<QBYE?3Z
M3R]C7',MB8,@%V@[3V<%IQ(7C0/;7$TCG'J=!T-'F%"1Y7%)=CO'8V)1)H@4
MI9,X_P"IH*F`B<D8=A!FBH?8J;\_^B`P@58?L`('Z0-PEVO[6R\TN&0-`&ZN
M/Z)CC1L_[MI.#9OV8)#9?4!$FD/\[OF^BP:7N_4=2/Q?K$=6_2.;<\JT=/4L
M4_BM?F6969B2]9.$L1JHB8CE2-4,#2;:BD8H*`JQ7(BN!!#<`%3PW'7<[AO9
MZ#<>-7UA';G[:V@^\"-S2'F%Q]G=,TD5#HGB*4--#C+U*XZW'D+H;R.4N'NT
M_H5!PU#%A\SA5M?-T7>/<-*2Z>.8MF@4BTO7SBNN8G[MNF,Y*NEWBH_!)JQ<
ME.;Y[`'Q#7(E]V4.]LXQM-E"QLU[MI+G$>C&WWJ>1\COJQQ/:X^.`&)"\1%R
M3W<WD[W>C%-@/'T&@`>4N%$B-QQBE-R,RXBVP-8&*_=%?N"B5K'Q+39HQ,X4
M*41.[>$3`2I$`5%UCCT@.XB'7[GO9ZTY1N-]<[-&(-ALQI]J\$1PV\?Z.(O(
M&,D@`+8VUDEE<=(-21[7M7('V<43+AVJZ?CI&;GG%U/`"N).``Q*:!;*^6.=
M*^F34!`HB4AE=NZH4/\`2*E`1(4Q_/I`1`H>&X^8](.4;)]A[DZVB:\68-&E
MWK&GXSJ5`)STBH:,*FE3RAMU[[Q$-9&O[@\@\WW5,-PGLLC9,!02<DL=PI6I
MF;J[590PG4&.CU474>B8QA$1!HVD`1)\DTRA\-?<;X$N4[ER?X=]OBW1YDDV
MN]N;&-Q))]C"YKX6DG,1QRMC;X,8T=%UH[IV,%CS"8P``3Q,E(&6IP(<?E+=
M1\I*=GKN,N.D:(HOO=QSU:L/\2IFA8L;2$MG+DS-(8`Q/`P>RMA=/;>R>'M\
MG$MBB"QUXJFMG94U""'9=N4!$0WT6314^10^?TW?(_T$QFWB7-R`)M))JVS1
MC=BX5Z`3D&`,JOD6,9I'_OK,OPAYVR["'87.(?M:+)XZJV)HM:-$4-WNY<..
M,UJX4<B,H*X5QQ"Y.QY29&^U?(5:J4-7+8VG(M\S=K`^F(1HQ<S3&50%5!RW
M>"ND<JHFZ04`IREDTFM.B@F]@#C;@_/&?\URF9,:U/):.-,;UJ3J,'<H=G/5
MQC,V.S.V+R9<P+]-6+DGR#&,[2'J4EB(@L<Q2@?I,6K-Q(&"M'9F]N'A'G2C
MRU$MG&S$4,A),EVK"R46AUFCW"MNU$3I-96!L5:C(Y^V=L%3`H1-0RK942]*
MR2B8F(,6L.(533@IRMS7[;W.QUQ?L=ZF+'@YMGB1P5D>ER+IP[K[85;:I3XG
M(]1C'*QTJO,M72K5\N1IVTG;0RB*Q3CVSIVBV$5"O4"&PB'R$0^K46I5]_=Y
M]W62XMOUN-'&9PP?\A'[%HM>+HHR1FVF(V$RB56(B8>*4*NTF,ES;9=-=%)=
M-9O'-E4U#I*K+)IDJS:VN)R7V]OSVA87TL;RD]PA"1Y!<E[VDTLZ=4RQ(O+C
M"XX;/2$>,F=E8S*[IO:[J"2@"Z3=E4C8PX^G;H=:0KG%"[H,E/5&U^`AHM&$
MAX&$B85NB#9O$1L3'L8M!N4O05!&/:MTFB2)2>`%*0"@'AMJ+!1->X+[0O'S
MEU2K'8\=4^KXBY&,X]T^JUXJL6TK\+;I9!,ZZ%?R3#1B*$=,1\PJ'9&2[7XD
MR.<JI5%$R&04+)KB,\EW?LW3\A)>WMA:JSS1:-MF(I+).&+A#NA#UD'8L<9&
MLT(YAGJ8"/9=1S4J*9B^7@`AX"&B.S4H.BQ7$9,R'6,1XZO64[J^)'5''=2G
M[I9'IQ*'9AZY&.91[VP.8H'741;"1,F^YU#%*'B.B`5P"HT<4^9>2\7^ZQ5^
M3V<VDI4B\B[2W4O\?,BNT09XCY`L8T]`>E()Q[E<J\6X@7C01^R#6/`=@'<-
M5;2*MH%?/$-A$/D.HM2`\P_*'Z=$6_HBA7Y7(=WD_<!$B:@#&TXHD63*H0Q0
MK<<.P@;80W'X@("'S#7PB^,J,S_%ANT6ECVFUVZH<T.!'N4.%#]\$'P(7:#M
M\_3P*VS'Z2;$9_K'?VQ2FXS@:=))MT7Z[VL.QZ>AXD09:',?PZ>Z@8R4HP`!
M_OE4<%#Y!KFGM7QWA%[:PVU_)/M%V\"DC1[Q;5Z:FDMN(17'4'S`=0T"J]8W
MV[W*-Y?$&W$8Z'T'_(<6N\U&IQ%MR&M5IV(J\0I$2=Y+"(&FKDBD=4/P61*!
MHI$R"O2@_EG;)(%#JK%4`B0D$.HQQ$O97F/<J7B6_6G%=F?97?<%E@PW.Y,:
M7?PT]#;-+7>A-<21M#W22->&LT$:B^K?3-OV9M_:27]P)(]J,IT0DT]-OKFH
MQ:P$T`%*FN5,5.JXVA>-]>M,>M*5J=$R#INT!+TJI`*JV1].B@LU2.4`\$C$
M`-@'X:Y1XD>87>U'<I[T3QMB+2R1D8;[-P`+&Z&L=&T@#",MI0>"\'?"Q;-[
M)D>DZJU!.?CB2"?/5<;?H.OR5?CS+3#.L5=IW@;P+!BL_E'LTCLF_<*$%9NF
M[7*!P*FLLIL1,P;["80UZ7W!V/CNY\;M))KZ#:.)0ZM%G#$Z:>2Z;Z,SB"Y@
MD>*@,ED?1K"*Z2X@^2VFZO(;MX;$Z>^=2LCG!K6L.+16AH/$`8GS*/+*;&&3
M[X1$<J1,HCL[E%B.WR@!OX]E!-&/;`8?'I`BA@^^/GKYF][]LV.-CY-CM2UF
M8EN'-DE/ET-#865SII>1^T*YGXW/=.(]X?CX,%&CY35Q^<>9/CX'%Z,'OB_`
M,@V;_P"'":^@_P#3M)/P_25S_F&^_P"2W7%G=TUY8T_^'%]]Z>CKO:N+T!X^
M`>8Z(H4L>RP\SO=ROMX2`)3"?MP49YC&H*B/>BI+DCD[K;W>8;D.8Z*KRM0;
M%U'&.3[2*K-$X;=P!U5GDVG4JOGR#92/M:>[^K>X!JO'T.&RC'Y<@VC0JB*$
MEA7+IW@7:NM/``4;Q3:4F8U,OB!5&*8[>`:+,>DU7JXN4C9N,CIJ'>H241,,
M&<K%2+50%6S^-D6R3Q@];J!X*(.FJQ#D,'F4P#J+2M[1$PGW2/\`\\.8'_1.
MT?H;:*C,*O\`?TTH".:>5&P"/_*S'0>`"/B-NGQ`/RB`#JE;'Y*VE=+I4\;U
M2?OE^L,54:;5(MU-V.QSKM-A%1,6Q3%9RZ=.5A*4`*4NQ2EW.H<0*0#&$`&+
M4J._%#CA?_<Z]R"\Y\KU9F8KC\')"8S-?;X^:*LXIA6V-R4LM9I+%ZJF5%_=
M;*T8-&YVB'<49)**KK`0I`ZZMI(:VBNSYCR,PQ#B7*.691,BL?C7']QOCMN<
MPD*Y3JL`_F_2]0>("Z,S!,/I-J+6!4T5%_VI:+(<R/<XH]TRTH>TNF]@N_);
M(*T@4'A)>Q0*OXU$)NB+]9%&1+S,1PE2,`D!!`$P#I``U5M=@U7YA\?$?,=1
M:4:(C1%YD7"PT&1ZG"Q$7#IR4F^FI%.*CVD<1_,RBWJ).7>D9HHE=RDBO]M=
MPH!E5C^)S".B+T]$4,_NR6R2RY*\9O;CI+]RC9>8F3(ESE-6-$QGD!QUQW((
MV.]OG!2`!DD9Q6,%,AA,!54F+A,0'?;19-^EX*,'^HLXJ154#CUR.HL&C$5Y
M"#2X[VM"+;@W;1B-?9NIO%2O4F/4F"<2E*,"&';I*W;D`?`H:JR8>BG4]KSD
MQ_W6<)L,Y&DGQ7MU@H;^6>2C"<QUPO-`(C"OWKH3")N_8HPC25_]+X-M18N%
M"I`P\P_*'Z=%BM_1%#/RCD#,N3MP$H-Q#\/J!A[[9JX#?^&8X/)PDH'3M\/+
M7PQ^+O<G[=\6F[/:(B/=MN]>.-__`&4/TVN^;+JNS/`X1-P.V!U>O-D2/\5W
M@0E_Q!+695NV<E1J47%=)1-+V""KT>TZ2^8MEC,D'C]0/@"`*#\Q#7:;LUO'
M*IK*"\8S9K/9](K<7EI9PQT^HXQ,EE/@(M1\2,UZ-R*WL6R.C)N))_HQR2./
MRBI:/[U%P>=S/*CE-/(A5B2=.NS*(;(S[%NLC%MK#!QZ$5(Q1P4W!F*I&A%V
MY3#TJ$.8""82&VXP^(6>^X/W@'=#6+O@/(;:VC%Y$QPMXKVTA9;2P'5^JUMC
M;+""=+VN>UCG.8^GFN)MBW/CQV4#1NEH]Y]FXC4Z-[B]KQXT)+7>!`J!4+MX
M3-K9&,*BF\+^\*!"E*?<3F-L4I"E*.YCF$0``#Q$?#7(.P]\[:+:A#;W+"QX
M``#LR<``*U).5`*DY+Q%UQ>0SU<PUKX?VP2Y,WDJPIB#15_6XVS2*SJ;5@+8
MU;`OZ20*B6/215DR^@:NU&[?K,FI\3[&$IBB&NP%C=;QMO!XK"2YVJUY9<R2
M73K3<&,#_9S!HA:UUP/8LD+&:BQ_5VEQ:YI"]5DCMY=R,K63/L6`,$D1-*MK
MJ/H^D14TJ/"HK5,2S),S2*KAO,1T:P<&`XE*2NP;,JA1W#K06:L")N$Q^!TS
MF*/P'7ST[_[_`+[:MDM=ZMK6WN7`F@LK2,.&.+',A#7M\',<YIS!*Y9XK:VS
MP'VSY',!_:2'YP78>8@%.]X*J"KA604$"@)L@V;<"$(F7P9PGD0@%(4/R!KN
MO_3QD=-V!ED=34>17V0#1ZEOD&@`?(%QYW;;IY2QH_R<7WWIYFN]2XP32.=?
M)>/XA\4,S9Y<G;C,5.JKLZ2Q<'3`)3(%B.2"IC$J2F_J$RSCY)=<A0$P-4%3
M>11T5`J:*)?V[,/>YWQIXW03&A86XDV`^7I-UG2TVG*N7\FP^3+!/Y):,9@B
MMSCH.A24?'RS"*%NW.W3<K`D<AQ,/<,IO5DXM)ZIB7O;X6YK7FAX\Y+<CL1<
M=JA'XQ=FQJ^GL'Y#O-TF7</>I!)U!HVF/ME2@6S6"B+`T430<(JF.5S*B0Q1
M*<!*5:1D%,'['7)@W(#@W4JM-2(O;SQXDE,.6#OK&5>KUV-;)2..I17KW'LJ
MU%VDQ*;?[2L<K\M18N%"IB=%BF$^Z1_^>',#_HG:/T-M%1F%5P]C/C=%\D,H
M<@HF1RYGW#ZM4Q]3)-C-8!R>_P`8S4@I)V.79J-IYTS9/TII@V!N4Z"*Q!(F
MH)C!XFU5L<:!)U[HN$.4/#WD'3HK-.7LF<I\(S$NQOF*GN;+;;+34[HUKDFT
M=3E`OD$XF5(@D]&=9$'WIBI"Y8.TW*()"<Z:1&D'SJXEP9S=@SD%QCQKD?CU
M7J]2*`\C/PQ?'5<CHF';XWM<:5-.S4E[%0S=HR:OH=^H(@H"1/5MU$G)0$BQ
M1&+600<5ZG."G2>0>&W*:EPI%%9BQ8"RHPBT$0,99R_&G2JS5JD4OVC*.ED@
M3*`>8FVT1N#@J@_]/G<(N!]P)A%/U"I+W_".2*Y""H8"]V4:*5JW^F+O^TJK
M%5QT8"^8]`ZI6Q_JJ\YJ+4C1$:(C1%\UED6R*KARLDW;-TE%W#A<Y4D4$$2&
M46764.)2)I))E$QC"(``!N.B*L/QHLO,'EMS:Y*>XKQLQO@[(5'B)*6XP86=
MYVO=RIC*&I%4-%N7DU26U6K-C,Z6L:*@.7:JID03/*+)$`P]?35L-``"G.\U
M\1>Z)RPXTY+PQD#`W"]&$EX]I86LA3<RY4DKC&3=.?M[-%NJLPEL>M8UY-+J
MQHM4TEU4DE2N#$,<H&$08*`@'JHSOZ<WD@K4<VY6XNS[P[:)RU7/Y@TQ@\,=
M,[?(-`3!K8HUN@<0!)Y,TYR998NW5_\`2@'P'19/&%5<1#S#\H?IU%J6_HBA
M"YC.W$7R9M;HH"D*D33U$5#)E-N0*\R1[J7640#95(Q>H/$!*.O@M\<4]WMO
MQ/[O>P#1-[GMSF.(!P%I$W4VH-/2:X`C$$&A7:?MI''<<&MXCC228$5_>.-#
M\AR7ZQO;&KI5)Y8)!T#%N)`74!05I!X)=A+'QYEQ,!55`\!4-^Z0)]H0$>DA
MKVAYU9W[FW'*+F8;?%0.=JU32D8B&'77TB,W.]"%OI.J=#':-^VN2(%EDQOM
M3EA1K?K.I3`>&;C@.I#U*_D]A-P]@<3\?$K52-B4(6&IBR"3R%<OI%0?1(NF
M[HAPD5&[=HJNLLJ`G'81#I$P!KOKQ[NG8[YLFXW7([:SEX9:V;+6VVQS&R6L
MDLSC[)DC)`X3EC(Y)99)`78$C27`+BR\V.:UN86V;Y&[B^0O?,"0\-:/2(+?
M5J2&@##ST6S!*XEILA2)-C2*E"FL4,JO*2S*+2*YBGBSYS%IR$>94ZP1R;1P
MT,<P(@38HB(>0:V\<_\`C7!]TV'==LX]LM@_<[)SY[B&W:)+>1TKX!-"7%WL
M1&^-SB(PVC22/5`4O#R+<X;J":[N)6PR4:QSC1X#0XM=2FJH(`K7'SI-;UD,
MK]%Y6K<N4)6$<.V498C;J+H'06.FI'S'1N=Y%N3EW(N'4J@80-]LHF#7&7/^
MY,=W;S<9YQ(/M:PDDB@O#B]I8X@PW-*F6W>15LN,D1.O](PN"\SM.RNC>V]V
MX'W>4!SX^AKDYG@X=6Y.RP-$Q6^6Q[UN([U"@)%.<IFAE"KM=_,#)IF%1N('
MV`0.3S#80'7SH[C\SW.\OI-G;(X6[7$.C)#X_.&G5&010AS<Q0@THN8-EVR)
MK6SZ1JIGD?GP/R')28\"TU2X(454()2NKW9UTC"`@!TRHQ3<QB[^9061,7?Y
ME'7UJ_IY0R1?#X7O!#)-^OG-KU:!"RH\1J:X><$+@KNZYIY=I!Q;:1`^?TC]
MXA/1UWH7%ZKP^XC9V?-?W%N(?MPP;\LACW'=E3SUR3;M5Q%JL>!B%[!&U*2Z
M![8+M:BB=,Q1WZ5;&CN'438*LVX-)5ATI2$*4B9"IID*4B:9"@4B9"`!2$(4
MH`4I"%````\``-18)!.4V"X?DQQUS'@>;!(&V2Z)-P#!TM^Q&6+T_K:K-`.P
MB!X6RM&CHOTI:*@T-53X]BWD4\XT<W)O`^17@5V#SFW?8KG&4BN+=G$9CI$D
M_4J!5^K]V5V]?$DH4F^W<7?(E^6JMCA4*\'J+4F#>Z6H1+V[N7YE#E(7^2ME
M)U&$`#K4,T33+N/]XZAP*`?$1VT5&85?[^FG,7^=?*<G47K'%6/#`3<.H2EM
M\X!C`7S$I1.`"/PW#YZI6Q^2L6\]N'E2YO<;[EAB?*T86;M&LN+;8NEU*T[(
M\2V<?@$H"A`%4(M^*IV,DF&_=8.50`.L"&+%K!H:JH3[8?,R[^VQRRLN'LZ(
M2-7Q;:[<;'&>JO*]X0QQ=89VI#Q>1FR)"G\()R((R"B11(]A%N\7N"@WU5M<
M-0PS5[MNX9R#1!TU6:R$>_:IN&SENHD[8OV+M$%$5T%DS*(.FCINH!BF*(D.
M0VX"(#J+2J*/.WC%E;VIN<=4S]B>+<!BAQDTN4,&6,$EQ@6BXOE9.QX7LCA(
M#%9KLV;ITP33.("^A%BJ)]1R+E3JW`ZAY5<HXJ<I<4\PL,5C-6)9A%Y$3;9)
M&>@%7")Y^C6E)%,9BGV=HF(*,I:)<&$H")2IND!(NB)D5"&&+400:%..T47E
M3D["UB%E;)9)>-@*]!1[N6FYR9>MXV)B(M@B=R]D)*0=J)-6;-HW3,=110Q2
ME*`B(Z(HM/;[YCV[G!GWF-DBMS[K_M8QM+X_Q)@V`4BV35.P3#)K.S-TR8Y>
M*1R$[ZJR$79BW;++=M".4;@*15NX(ED10>5:_O.<K%.-/#.UUZK2'9R[R%45
MPUC9@U5`LJ"-A0!O=K`S3`!4*6'K+A1NFL7;M/W[4-]S!HC14IVO!?C?'\3.
M)V$\$M4$4Y2HTYDYN+A%,A/Q"^V'JG[H\.<@;JE_B"0722,;Q!NDF7P`H`!0
MFIJG:`.P@/R$!T45"OG#5YWVV_=<?Y&H;,S.%B<E5WDAC]BU*=NV?TR[R#E_
M;ZFD4H_^Q,_&=AA)^R#?I\-A#5Z+<,6J]-C^]5;*%(J&1Z/+-IRG7JNP]KK4
MNT4(J@^AIQDC(,5@,0QP*H"*X%4((]2:@&*8`,`AJ+2N]T1,1YC\;Y3*K9C>
MZ,V*ZNM>8C'OX4#)HJ66"(HHY1(S54,1/\7BUEE!2(<0!=-0Q`$#%(`]!?C5
M^&'=N[ME;]P>`Q";G>VVYAEMJM:;VT#G/:V-SB&^\0.<]T;7$"5CW,U!PC!Y
M7[:<WM^/2OVG=G%NU3/U-?B?924H:@8Z'@"I'JD`TH2HDU%IVIR!XV;924,_
M9F,DM'RS5S'O6QBFW,0[5X1%4GVOH\?IU\8[^UW_`(EN;K#=X+JPW2`EKH;B
M-\+V$'$%D@:X8^3'-=BVBSW&$3VSXY87"H<PAP/AB*A*0PRJ=%@SCP=%!%`Z
MSI4.X`=QXY!-,YQ`1`1[+9$B9?E]H0_:UR-MO>7<-OV^WVOVGZ",ND=CZTKZ
M`G/'2QK&#^\1ZR\#/QMKYWS:?2(`&&31C3Y22?F\%TDKE[U;&%0%T0091:K4
M-U2[`4\K)N^G;J\/%UY#KVK>N_,]WMUA;A]3#9NCS'6XGD\?KK\%MQ81S2NT
M^M)7+ZC1_P`$GUGR0O-G(N=T!W)FR+=R;N`)E3M4P;I+'-OXG4;)D`P^8F*(
MCYZXSY9W)W/E,C+F::DYB:R0EV+C&`QKSCB71AFH]7-).:\YM^Q1V8+`WT-1
M(PRJ:D?/6BW,;8?R1FF:;Q]5A7BK(RI$WMD?(N$*W"MA-NHNZDCD!%4R1!$2
MMT1.LH/@4OQ#V+M/V.[E]ZMZBVOA]A.^Q+@V6^F:]EG;,KBY\Q&EQ:*EL,1?
M*\X-;F1JWWDVQ\8M73;A*T2@5;$T@R//0!HQ%<BYU&C,E3N8WH<1C*CURBP8
MF.PK[`K472A0(M(/%#G<2$DX*41`%G[Y9140W$"]0%#P`-?T)]L.WNS=J^!;
M9P'8:NV_;;81ZW`!TLA)?-,^E?2FE<^0BI`U:1@`NI&][O<[[NL^[75!-,^M
M!DT9-:/(UH`^2J17DMCCD_DF.@X?CIR-K''5`S>:;W"=D</,LIVE_P"L*R3B
M5:HYE[-$0]<7CDR.>LZS-Z90ZJ9BBGV_M>^KQ8H,U#]CCV-LPX7S*ER/Q?[A
MMO9YV_$9J5D;Q:<*1-H/8GEF(J6S%M#>5OSLL^UG.\;OD7`VX@4Q1(<A#%M5
MD7`BE,%.=AF!R[6J#&Q&<LB5?*>1$'DF>1N50HA\<0K]@J\4/$H$JQK!90:N
MV;$2D65*Z$JR@"8"$#PU%@:=$E_(_'?*O('X"TXX<CZ9Q^8$CY=M:WD]A1EE
M>P2#QT=H$4^KSN4M4+%P@QZ!5P.59F[!0YRF\.D0$J".H4$K_P#IN"3TO)6N
MQ<W;5(7&:FG]EEYXF'6!';VQR4@K+/)HSD,AD<D?N)58RYE"&*8JH]1=A`-K
M59Z_(IA>*7'OF;@N5BX3,G-.,Y*8IB81_'-HFT85:U[)H/.E`L*X6R6SN3YQ
M)MV`$/WO7M7;EP!@`5@$.K46)(.0Q37^2_MW<U^7D%-X^S%[AT?#XAFI0[IU
MCC&/'&+J\=)1S:4"0AH^QR:F07$W84X\S=`YDEW/I5%T04%(1`NU5U-&0Q3;
M,'^Q7EOBS>"9,XV^X3:<>7<8]6'?/5,&P4E$S4*LX;NU8:?@WEY=Q<U%G=M4
MU>TX2/T*IE.F)#@!M$UUP(4Y."ZUFRJ41.'S]E&JY@OZ<O(K?QG3\=_RPC%X
M)3L!%L7%8+8;(C^)M1(H*SA-9--7N%`$B]&YHL33HHK_`'$?9AHW.7,,#FNM
M9.2PE<%X(M?R8LA22VYO?4XL$4:Q-F;EL%>!A88N/ZV2RYS+%=-"-RB4HH;F
M*M=3!=/Q]]O;FUQ6@H"E8D]R-Y8\;P9V2#7'V7^/<1=H:+B4')5'$169(V04
M;)7F0MQ.1%%!X#9`3!TI``;:*EP)Q"E+RGBC&N;J-.8TRW28#(%"LB`(3%8L
MK$CZ/<@4>I%PD(]#AC(-%/MH.FYTG+=0`.F<I@`=%@"1B,U"@W]F&_<;,BR6
M5_;EY@7+CY*2AD0D\;Y)AB9(QY-M$53+)Q$RN15NZE8AN8W2W"28R;QN41%-
MP!OM:+/744<$ZB/)[T#!@6*>J>W%/O"E%(+<JIR`BE3[`)0<K5QHS4:"J/@8
M2D6(3?PVVT4]#RIM6;O;0YY<U6(P7+GGQ6J[C\54G`X@X[XDD(NBK.$#]Q!2
M6<6"T1DG:#H*?:3&4!VFD;8R9"B`:*ZFC()Y?%W@>^X2<6+I@7C;EH$[_9;3
M*W:/RSE*CL+0U86*73K\<L>0I<!*5E&4CF,%!]AJCZU,2*J`H<R@`)3%":FI
MR4?.>_9!S-RLO"&4>0_N&6NYWN/;E9P"D?@^'A*W4F*+GUS>/J,`POK=G`-"
M/P!8XHE[ZJI0.HH<X`8"NH#(*5OC)BCEMBY=]&\A>4U8Y'59O76476%DL*,<
M;7EM+M728&E[+9(JV2T?82JQB8I&+Z%!518W=.H(@(&+$TZ)=<N0V4;!C^=B
M<,7FMXWR.[]`%?N5MIBF0("(!*1:JR0O*HE.5P\D9W&$612'U:8(JJ%4$#@4
M2"04ZJ";D#['>8.7615,K\E>>SRWW0D,SKD8I7^/L'7X6$KT>Y=NVD)#PS:^
MD;,V"3N076$1ZUE5EC'44,(^%66J@H`EOXQ^V=S'X:LFU3P/[B!'F+B2B3];
M&63^/K*V5IN5=\FYEPKW_,5*1JJTD45!-Z!PB@98_<.F8XF$2%P.8Q4X6HL%
MIJ_YPW]G^$-$7EOHF*DQ*:2BXV1,0-B&?L&CPQ`WWV*9RBJ)0W^6O&W^S;/N
MA#MSM+:Y+10>UB9)0>`UM-%NBN+B"OL)'LK]%Q'WBM#^%*K_`,,5S_<47_LF
MO'?R=Q'_`&K;?]-#^8M_VCN'[>;\MWX4?PI5?^&*Y_N*+_V33^3N(_[5MO\`
MIH?S%/M'</V\WY;OPK/\*58/*L5T-O+:#B_#\G^JZ?R?Q$&OV5MU?_6A_,3[
M1W`_X\WY;OPKVD446Z1$&Z23=!,-DT$$R(HIA\DTDRE3('Y`#7GH((;:)L%L
MQD<#!1K6@-:!X`"@`\R_*YSGN+WDEQS)Q/SKZ:VK%'_C_P`ORCHB0;'V<DLD
M9'N5$AZ9/133'Z!TK1.6!5BV41G%'8-F$.SCH]:1(H+@B2ZIE#KDZ2)!L41-
MX%:4%4O.BB3!+*\`MEEWAXL;8@L32LI6@\H:+,%<.S5%/9LG(]SJ%R!50^T)
M`2$X"F!NLHAHK3"J4_11&B+(`(^``(C]'CHBQHB3[*&1(_%=,E;O+1$W,QD.
M4AWJ$$DR5<H)*&!,CEQZ]ZQ22:`L8I#'`3F*)P^R(;[%0*FBW,<VMY>Z/6KD
M]A%*XI9HTDPA"K.@>KLX]XJJI%BX<E1;E.X<QW:6.`$`I#*=("(!N)#@:+M=
M%$:(C1$:(C1$:(C1$:(C1$:(LAYA^4/TZ(M_1%IJ_P"<-_9_A#1%\]$1HB-$
M1HB-$1HBXG)%U98YH5LO#_H%&M0CR122..P.GQ2=J,9`.X#U/9%5)(-O'<^B
MH%311WXMRE<,+X<;Y"9X\-;6UWNJ<_DB\R\L6)*^F+/)@U;1E68E36D9PD:B
M8"*.A*5J5XHHF3N`4YBU9D`FG@I*[!.H5Z+/)K,Y%^<5&K9G%QC4SJ3D7[]4
MB#&/;([E336774`IE%3IH(%`QU3D3*8P1:TC.!LQ3N8BW]_(U2/K\35K4I5X
M22C9=2:;3HLP6-(]#XS5JBX*Q/VA[B(=D_>^SY;B5(`7I6[+CIMD&.Q'CZ$;
M6F_N8\)N=4D'JK&LT>OB)`))V1VT0=/%7;P5"@V9HD!143D$QB%,`B0#"IR7
MJ8ER?_,=M<6;QDUC[%C^YS%(L:,>NLZBG+V+4_<R<4LY21<^AD$!Z@35+W$C
ME,41'8#"5(HF^\DKK;K7=L=X%QU^/0E@GK"$_-3"KF0K+!Y7X!!=RNW;RL<9
M28-#J*IJ=]PDAVCF1`J8J"!@+56BGI')*SA[,\M>K=D?&]OKL=7KIC5ZT2?#
M!2;F6@I6/>"8J#MDX>M6CQ)0@@43%4+N)5"CX&`Q0BA%,1DDFYL6AJ:`Q[BE
M1Z9H3)%RCU+`=$%%7"=2K[ILX?%2;(%.NY<.WRZ)4$B%,==5/H*`F';5"K,U
MUK3.-OK^5\:XOG\7,ZI5[_&NTJD<+`5]9HIG#LC@U"?BFS;\-CE`3;$*HV37
M6%`J@`*ICD,4"E,*UQ3F)^?A:M#O[!89)M$PT8CWWK]T82I)%$Q4TTR%(!E5
MW+A8Y4TDDRF564,4A"F,(`,6*;A?L[WR#E\<UVLXT02E<H6$L96R6^9%"31B
M&GIUY>;FJM%)"[B&R+%QW"`J[[R?28%DDSAT:M%D`$N5^N!J3`.)5O$.9Q]V
MW@LV*:GHV0>@8.I-X^FI=1)5M!PS%DS456<*`8=@!-,BBIR$-%`*GR)J]-Y,
MY9R/0XVTT#"2%GD$IDS*T)(6,&45'ME7W88MXE5ZFD[DY<S(P.'90+VF2)B&
M.)A4Z2EEI`P)3I;Y=24F"/)_A:\K(*-WRS2.37(U:$"-CUI.1>3,THF=E#0L
M8T0,=PZ4`?#8B1%%3D3,6`30F_+^WR&%'N5H[&L.!H:149S2LE8W+"OD%:32
M8Q<9!J*,1DK!87":Y57""94T6J6QCJ"<W;`L].-*KJI+E#:`?89/"XS27A,L
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M(@(;](Z+-O4]5VAZTIFF=I14X)U6L$8W?,9N$C).,6AGF0Y^*0[-=]-`.TD'
MD71ZV0>XF+E))1\L(=*?:*!Q*5H/K+?Y6WZ<HF(I(*TD]-8;G),Z/&O639TZ
M/$_CJ;GUTF*;-%=P*J+!NJ5'H*)^^<@E`1#;1&BI7:X*JZ=*QM`5=M!.(*+A
MR=B,)(!VIN80.5-9Y8YV/%,#1$A.R:BZY6ASJ+(-S)E5Z%.I(A1V:;#1["IB
M&Y\FYZRQ<C,Y2M-_$M#JS./=O9RX0IFRZU2_!2H)'%2`,=X4CAP!@1:E;&!0
M2F(!1JRI4`#)+OQJQ7-XPH3DEM527O=VL$A=+B9$X*IMI:7$@DC2KE,9-86*
M)0!0Q=R"L<_2(E`!&*.-3ADF\X[R53)7D#FS,5HD52LH1JACK&;5-@]?.IYE
M$+G0G"51NV054EI)R]:ICV$.I4H/@$P`4W5JJTP`2X\=\:V"`<Y"RE>&)HN[
MY?L2DZX@E3D4<5BNIK.%(*#>G3$R82947'4Y*41!,0(3]HIM11QK@,@DBF9"
M)=9ZR5G?(43/J4+`;*$I5011@'T@J\LCM8/Q.=CF((!ZU&*>2*FRQ1[9!.FI
MU;IAHF0IU*6*LUPV3<R-LY.VCUI4ZK4PK.+T)-BYC7\RYEP6<V&Y+1KY)%\P
M9&2=BS9%63(JL!3K=($[8F*'`47"97O2H<E,>TV=KEHG*K6ZNXND#!P4,YE"
M6G(KE9PRA%G0EZ&*3:NMTE#HK.5"-FCHW=5,0`*8'19#U3XK@\*3%TR)R-R!
M?;77':\U5WA\?PS!5-ZWK5`K:3EU^/OD)ART*A)S#CTY6Z"2`=UZJZ56-VFQ
M0,!#0-H,DMW+&0L:^,D*!3V+U[9,K6&+HS4S1LY628QKQ7U,R]?KH)G39L@9
M(=I0Z@E+T*F\?`=%&YU\$L^.*'#8RI->H\"F4K&!8)MSN`(!59%^?][)2CD0
MWZG,B].=4PB([=0%#P`-%":FJ03E"XL]O;TW`].1D$7^594"V>>09.E6%?H\
M0HFXEUWCLB?IDU'AP`H)F4`RJ:9R;?O`W*M\?!)U9\8,LAY)H/':#B)**PGA
M2)86.Y+J-73=K9YURF0(R$!\9-)&0=.DW!U'2I!$=W#@W@8I=56I`U=2L8MD
MG^2^1UPOA*O(J1V/77\L:.R>LG,17J968\7#>PV/U2K3TR\Y*'2%!BP;`97H
M<"*HI(I`?3HJ<&KO>5EN4B38FILBRFEZ/>;NFED!2#C)&4=OJ["BT=_PP5M&
M)+.UD[`Z6*"R28"HLW2.0`,`F#46+?NI'+%8[EDCDU5H23HLPVKV,H9M:J3C
M]9HHV0<SL@@V+!R]QD4$5XB"1C4'!'*I1,H#-)MZ5,JKHYDS%D``VO4J1T.K
M8.K;JV#KZ1$2]>P=72)@`PEZO+?QVT6M9#S#\H?IT1;^B+643.8XB`;@.WQ#
MY!].B+\=I3[OYR_KT1':4^[^<OZ]$1VE/N_G+^O1$=I3[OYR_KT1':4^[^<O
MZ]$1VE/N_G+^O1$=I3;;I\!VW#<NP[#N'AOY@/EHBR*:@^(@(C\Q,`_Y=$6.
MTH']W\Y?,/(?/S#1$=I3[OYP_7HBSVU/#P\@$`'<NX`.PB`#OOL(AY:(DHS#
M-7B'ILRTQ]39NU6R7B9)A#J1B\,U90SQPAZ9*1DG,I*,3@#;U`JID1(L90R>
MP](>.BHI7')<SQDISVC8;JE7D:]*UV<C"NU+`VER,2N74Z_<*/9%^@NQ>/47
M350[@$TU.L#"1,`,4!`0T5<:E+YVE/N_G+^O18K/;5'S`1\-O$P"&P^8;"/D
M.B(%-0?$0$1^8F`?\NB([:GR^`AYAY#YAY^0[>.B([:@_#\Y?/;;?S\]@T1`
M)JAOL`AOY[&#Q_+XZ(L=I3[OYR_KT19[:NVVP[?+J#;ZM]$1VU=MMAV#X=0;
M?5OHB.VI]WZ?,OF/F/GYCHBQVE`\B_3YE\PWV'S\_$?KT1':4^7GL`^)?$`$
M1`!\?$`$1^O1$=I3[OYR_KT19!(^X?9^(?$/UZ(MO1$:(C1$:(C1$:(C1$:(
LC1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(O_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
